TWD
ENTA icon

True Wealth Design’s Enanta Pharmaceuticals ENTA Stock Holding History

True Wealth Design’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.4K Hold
645
– – ﹤0.01% 1080
2026
Q1 		$8.15K Hold
645
– – ﹤0.01% 1042
2025
Q4 		$10.2K Hold
645
– – ﹤0.01% 856
2025
Q3 		$7.72K Sell
645
-31
-5% -$248 ﹤0.01% 930
2025
Q2 		$5.11K Buy
676
+325
+93% +$1.96K ﹤0.01% 796
2025
Q1 		$1.94K Buy
+351
New +$2.17K ﹤0.01% 1018

Other funds holding ENTA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
HFS
Hughes Financial Services Herndon, Virginia $755M AUM 20.43% 1-Year Est. Return

True Wealth Design's ENTA Position: Q2 2026 in Review

True Wealth Design held its Enanta Pharmaceuticals (ENTA) position steady in Q2 2026 at 645 shares worth $9.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1080.

True Wealth Design first reported a position in ENTA in Q1 2025 and has held it in 6 quarters since. The position peaked at $10.2K in Q4 2025. 9 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • True Wealth Design held 645 shares of Enanta Pharmaceuticals worth $9.4K as of Q2 2026.
  • True Wealth Design left its Enanta Pharmaceuticals share count unchanged in Q2 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1080 holding.
  • True Wealth Design first reported a position in Enanta Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • True Wealth Design's Enanta Pharmaceuticals position peaked at $10.2K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.